A Novel GTP-Binding Inhibitor, FX2149, Attenuates LRRK2 Toxicity in Parkinson’s Disease Models

Leucine-rich repeat kinase-2 (LRRK2), a cytoplasmic protein containing both GTP binding and kinase activities, has emerged as a highly promising drug target for Parkinson’s disease (PD). The majority of PD-linked mutations in LRRK2 dysregulate its GTP binding and kinase activities, which may contrib...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Tianxia, He, Xinhua, Thomas, Joseph M., Yang, Dejun, Zhong, Shijun, Xue, Fengtian, Smith, Wanli W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4376719/
https://www.ncbi.nlm.nih.gov/pubmed/25816252
http://dx.doi.org/10.1371/journal.pone.0122461

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4376719/
https://www.ncbi.nlm.nih.gov/pubmed/25816252
http://dx.doi.org/10.1371/journal.pone.0122461

Ejemplares similares